» Articles » PMID: 22644789

A Composite Score for Executive Functioning, Validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) Participants with Baseline Mild Cognitive Impairment

Overview
Publisher Springer
Date 2012 May 31
PMID 22644789
Citations 272
Authors
Affiliations
Soon will be listed here.
Abstract

The Alzheimer's Disease Neuroimaging Initiative (ADNI) measures abilities broadly related to executive function (EF), including WAIS-R Digit Symbol Substitution, Digit Span Backwards, Trails A and B, Category Fluency, and Clock Drawing. This study investigates whether a composite executive function measure based on these multiple indicators has better psychometric characteristics than the widely used individual components. We applied item response theory methods to 800 ADNI participants to derive an EF composite score (ADNI-EF) from the above measures. We then compared ADNI-EF with component measures in 390 longitudinally-followed participants with mild cognitive impairment (MCI) with respect to: (1) Ability to detect change over time; (2) Ability to predict conversion to dementia; (3) Strength of cross-sectional association with MRI-derived measures of structures involved in frontal systems, and (4) Strength of baseline association with cerebrospinal fluid (CSF) levels of amyloid β₁₋₄₂, total tau, and phosphorylated tau(181P). ADNI-EF showed the greatest change over time, followed closely by Category Fluency. ADNI-EF needed a 40 % smaller sample size to detect change. ADNI-EF was the strongest predictor of AD conversion. ADNI-EF was the only measure significantly associated with all the MRI regions, though other measures were more strongly associated in a few of the regions. ADNI-EF was associated with all the CSF measures. ADNI-EF appears to be a useful composite measure of EF in MCI, as good as or better than any of its composite parts. This study demonstrates an approach to developing a psychometrically sophisticated composite score from commonly-used tests.

Citing Articles

Impact of the polygenic risk scores for attention-deficit/hyperactivity disorder in Alzheimer's disease.

Leffa D, Povala G, Bellaver B, Ferrari-Souza J, Ferreira P, Lussier F Alzheimers Dement. 2025; 21(2):e70003.

PMID: 39998851 PMC: 11853731. DOI: 10.1002/alz.70003.


Neuronal and glial dysfunction, white matter hyperintensities and cognition in ageing and Alzheimer's disease.

Lee A, Howard E, Saltiel N, Hayes J, Hayes S Brain Commun. 2025; 7(1):fcaf068.

PMID: 39995657 PMC: 11848269. DOI: 10.1093/braincomms/fcaf068.


Individual bioenergetic capacity as a potential source of resilience to Alzheimer's disease.

Arnold M, Buyukozkan M, Doraiswamy P, Nho K, Wu T, Gudnason V Nat Commun. 2025; 16(1):1910.

PMID: 39994231 PMC: 11850607. DOI: 10.1038/s41467-025-57032-0.


Distinctive associations between plasma p-tau181 levels and hippocampal subfield volume across the Alzheimer's disease continuum.

Rich A, Oh H bioRxiv. 2025; .

PMID: 39975208 PMC: 11838288. DOI: 10.1101/2025.01.27.635113.


Impact of sleep disruptions on gray matter structural covariance networks across the Alzheimer's disease continuum.

Luo X, Li K, Zeng Q, Liu X, Li J, Zhang X Alzheimers Dement (Amst). 2025; 17(1):e70077.

PMID: 39886320 PMC: 11780114. DOI: 10.1002/dad2.70077.


References
1.
Morris J, HEYMAN A, Mohs R, Hughes J, van Belle G, Fillenbaum G . The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology. 1989; 39(9):1159-65. DOI: 10.1212/wnl.39.9.1159. View

2.
Schwarz C, Fletcher E, DeCarli C, Carmichael O . Fully-automated white matter hyperintensity detection with anatomical prior knowledge and without FLAIR. Inf Process Med Imaging. 2009; 21:239-51. PMC: 2864489. DOI: 10.1007/978-3-642-02498-6_20. View

3.
Gomar J, Bobes-Bascaran M, Conejero-Goldberg C, Davies P, Goldberg T . Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative. Arch Gen Psychiatry. 2011; 68(9):961-9. DOI: 10.1001/archgenpsychiatry.2011.96. View

4.
Mohs R, Knopman D, Petersen R, Ferris S, Ernesto C, Grundman M . Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997; 11 Suppl 2:S13-21. View

5.
Grambaite R, Selnes P, Reinvang I, Aarsland D, Hessen E, Gjerstad L . Executive dysfunction in mild cognitive impairment is associated with changes in frontal and cingulate white matter tracts. J Alzheimers Dis. 2011; 27(2):453-62. DOI: 10.3233/JAD-2011-110290. View